Schizophrenia is a chronic mental illness that requires lifelong treatment., Patients with schizophrenia are at an increased risk for numerous other medical illnesses, including suicide. In Canada, the disease affects about 1% of the population, or about 234,000 people (2004 data). Antipsychotic medications form the cornerstone of treatment for schizophrenia., Existing antipsychotic therapies fall into one of two classes: typical antipsychotics (TAP) and atypical antipsychotics (AAP). Both classes are considered equally effective in the treatment of positive symptoms. AAPs appear to be more effective in the treatment of negative symptoms. TAPs are associated with an increased incidence of adverse events (AEs) known as extrapyramidal symptoms (EPS); however, AAPs are associated with an increased risk of weight gain and metabolic AEs.
http://ift.tt/2v9zP2l
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,
Ετικέτες
Πέμπτη 24 Αυγούστου 2017
Aripiprazole Prolonged Release Suspension for Injection (Abilify Maintena) (300 mg and 400 mg Vial) [Internet].
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: September 2017 Source: European Journal of Surgical Oncology (EJSO), Volume 43, Issue 9 http://ift.tt/2gezJ2D
-
Publication date: January–February 2018 Source: Materials Today, Volume 21, Issue 1 Author(s): David Bradley http://ift.tt/2BP...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου